TABLE 4

Reported and prediction results of FG and observed and prediction results of F

DrugFGCLint,HLMaFH,in vitrobF
μl/min per pmol
PredictedcReporteddPredictedeObservedf
Alfentanil0.720.60a0.8900.6130.4400.43
Alprazolam0.990.99NANCNANA
Buspirone0.510.221.840.6290.3210.039
Cisapride0.560.55a2.130.819NANA
Cyclosporin0.990.350.4740.9670.9590.28
Felodipine0.020.5315.50.1550.0030.16
Lovastatin0.040.0935.40.1540.0060.05
Midazolam0.360.483.750.4760.1690.41
Nifedipine0.600.742.000.5940.3580.50
Nisoldipine0.030.11a53.10.5470.0170.04
Repaglinide0.840.89a0.7370.9130.7710.60
Rifabutin0.850.21a0.5140.4360.3710.20
Saquinavir0.920.18a51.30.0900.0830.07
Sildenafil0.770.54a1.070.7420.5740.40
Simvastatin0.020.1951.70.1310.0030.05
Trazodone0.900.83a0.3700.8810.7960.79
Triazolam0.980.45NANCNANA
Zolpidem0.990.810.08500.9560.9490.72
  • NA, not applicable.

  • NC, not calculated.

  • a Gertz et al., 2011.

  • b Calculated using eq. 35.

  • c Calculated using eq. 34.

  • d Hisaka et al., 2014.

  • e Calculated as the product of FAFG (eq. 33) and FH,in vitro.

  • f Appendix of Parker et al., 2005.